390
Views
30
CrossRef citations to date
0
Altmetric
Original Article

The Political Economy of Drug-user Scapegoating—and the philosophy and politics of resistance

Pages 15-32 | Published online: 10 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (9)

Samuel R. Friedman, Pedro Mateu-Gelabert, Georgios K. Nikolopoulos, Magdalena Cerdá, Diana Rossi, Ashly E. Jordan, Tarlise Townsend, Maria R. Khan & David C. Perlman. (2021) Big Events theory and measures may help explain emerging long-term effects of current crises. Global Public Health 16:8-9, pages 1167-1186.
Read now
William Tootle, James Ziegler & Merrill Singer. (2015) Individuals Are Continents; or, Why It's Time to Retire the Island Approach to Addiction. Substance Use & Misuse 50:8-9, pages 1037-1043.
Read now
Sam Friedman, Diana Rossi & Gonzalo Ralón. (2015) Dignity Denial and Social Conflicts. Rethinking Marxism 27:1, pages 65-84.
Read now
Samuel R. Friedman. (2012) Samuel R. Friedman on Stan Einstein's “Drug User Treatment Failure Blindness?”. Substance Use & Misuse 47:13-14, pages 1538-1539.
Read now
Samuel R. Friedman, Pedro Mateu-Gelabert & Diana Rossi. (2012) Has United States Drug Policy Failed? And How Could We Know?. Substance Use & Misuse 47:13-14, pages 1402-1405.
Read now
Samuel R. Friedman, Eric Schneider & Carl Latkin. (2012) What We Do Not Know About Organizations of People Who Use Drugs. Substance Use & Misuse 47:5, pages 568-572.
Read now
Paul Griffiths, Louisa Vingoe, Neil Hunt, Jane Mounteney & Richard Hartnoll. (2000) Drug Information Systems, Early Warning, and New Drug Trends: Can Drug Monitoring Systems Become More Sensitive to Emerging Trends in Drug Consumption?. Substance Use & Misuse 35:6-8, pages 811-844.
Read now

Articles from other publishers (21)

Elida Meadows, Zoe Kizimchuk, Juani O’Reilly, Isabelle Bartkowiak-Théron & Shirleyann Varney. 2022. Law Enforcement and Public Health. Law Enforcement and Public Health 173 186 .
Samuel R. Friedman, Leslie D. Williams, Honoria Guarino, Pedro Mateu‐Gelabert, Noa Krawczyk, Leah Hamilton, Suzan M. Walters, Jerel M. Ezell, Maria Khan, Jorgelina Di Iorio, Lawrence H. Yang & Valerie A. Earnshaw. (2021) The stigma system: How sociopolitical domination, scapegoating, and stigma shape public health. Journal of Community Psychology 50:1, pages 385-408.
Crossref
Adam Holland. (2020) An ethical analysis of UK drug policy as an example of a criminal justice approach to drugs: a commentary on the short film Putting UK Drug Policy into Focus. Harm Reduction Journal 17:1.
Crossref
Samuel R. Friedman, Noa Krawczyk, David C. Perlman, Pedro Mateu-Gelabert, Danielle C. Ompad, Leah Hamilton, Georgios Nikolopoulos, Honoria Guarino & Magdalena Cerdá. (2020) The Opioid/Overdose Crisis as a Dialectics of Pain, Despair, and One-Sided Struggle. Frontiers in Public Health 8.
Crossref
Susanne MacGregorSusanne MacGregor. 2017. The Politics of Drugs. The Politics of Drugs 249 287 .
Rusty Souleymanov & Dan Allman. (2016) Articulating Connections between the Harm-Reduction Paradigm and the Marginalisation of People Who Use Illicit Drugs. British Journal of Social Work 46:5, pages 1429-1445.
Crossref
Maria Elisa Smith, Natanya Robinowitz, Patrick Chaulk & Kristine E Johnson. (2014) Self-care and risk reduction habits in older injection drug users with chronic wounds: a cross-sectional study. Harm Reduction Journal 11:1.
Crossref
Samuel R Friedman. (2011) What Might Socialism Look Like?. Critical Sociology 38:4, pages 599-610.
Crossref
Samuel R. Friedman & Diana Rossi. (2011) Dialectical theory and the study of HIV/AIDS and other epidemics. Dialectical Anthropology 35:4, pages 403-427.
Crossref
Joan TrujolsIoseba Iraurgi. (2009) Political challenges in randomized controlled trials of heroin-assisted treatment for severe heroin addiction: a Spanish experience. Clinical Trials 6:6, pages 658-659.
Crossref
Samuel R. Friedman, Barbara Tempalski, Joanne E. Brady, Judith J. Friedman, Hannah L.F. Cooper, Peter L. Flom, Moriah M. McGrath, Karla Gostnell & Don C. Des Jarlais. (2007) Predictors of the degree of drug treatment coverage for injection drug users in 94 metropolitan areas in the United States of America. International Journal of Drug Policy 18:6, pages 475-485.
Crossref
Barbara Tempalski, Risa Friedman, Marie Keem, Hannah Cooper & Samuel R. Friedman. (2007) NIMBY localism and national inequitable exclusion alliances: The case of syringe exchange programs in the United States. Geoforum 38:6, pages 1250-1263.
Crossref
Barbara Tempalski. (2007) Placing the dynamics of syringe exchange programs in the United States. Health & Place 13:2, pages 417-431.
Crossref
Barbara Herbert. (2002) Patient Descriptors in Injection Drug Abuse. Academic Emergency Medicine 9:6, pages 658-658.
Crossref
J. Trujols Albet, M. Casas Brugué & J. Pérez de los Cobos Peris. (2002) Programas experimentales de mantenimiento con heroína: la amplitud de la distancia entre lo que podría llevarse a cabo y lo que realmente se hace. Atención Primaria 30:4, pages 260-261.
Crossref
Andrew D Hathaway. (2001) Shortcomings of harm reduction: toward a morally invested drug reform strategy. International Journal of Drug Policy 12:2, pages 125-137.
Crossref
Robert G. Carlson. (2001) Harm reduction from a broader political-economic perspective. International Journal of Drug Policy 12:1, pages 15-17.
Crossref
Samuel R. Friedman, Matthew Southwell, Regina Bueno, Denise Paone, Jude Byrne & Nick Crofts. (2001) Harm reduction — a historical view from the left. International Journal of Drug Policy 12:1, pages 3-14.
Crossref
Samuel R Friedman. (2000) What hath RAR wrought?. International Journal of Drug Policy 11:1-2, pages 37-39.
Crossref
JOHN P. CAPITANIO & GREGORY M. HEREK. (2016) AIDS-Related Stigma and Attitudes toward Injecting Drug users among Black and White Americans. American Behavioral Scientist 42:7, pages 1148-1161.
Crossref
Nick Crofts. (1998) Drug use in Asia: patterns, impact on HIV transmitted through injections and sexually, directions for enhanced surveillance and monitoring of prevention programs. International Journal of Drug Policy 9:3, pages 195-202.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.